• Something wrong with this record ?

Circulating microRNAs in Cerebrospinal Fluid and Plasma: Sensitive Tool for Detection of Secondary CNS Involvement, Monitoring of Therapy and Prediction of CNS Relapse in Aggressive B-NHL Lymphomas

P. Krsmanovic, H. Mocikova, K. Chramostova, M. Klanova, M. Trnkova, M. Pesta, P. Laslo, R. Pytlik, T. Stopka, M. Trneny, V. Pospisil

. 2022 ; 14 (9) : . [pub] 20220506

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22017204

Lymphoma with secondary central nervous system (CNS) involvement represents one of the most aggressive malignancies, with poor prognosis and high mortality. New diagnostic tools for its early detection, response evaluation, and CNS relapse prediction are needed. We analyzed circulating microRNAs in the cerebrospinal fluid (CSF) and plasma of 162 patients with aggressive B-cell non-Hodgkin's lymphomas (B-NHL) and compared their levels in CNS-involving lymphomas versus in systemic lymphomas, at diagnosis and during treatment and CNS relapse. We identified a set of five oncogenic microRNAs (miR-19a, miR-20a, miR-21, miR-92a, and miR-155) in CSF that detect, with high sensitivity, secondary CNS lymphoma involvement in aggressive B-NHL, including DLBCL, MCL, and Burkitt lymphoma. Their combination into an oncomiR index enables the separation of CNS lymphomas from systemic lymphomas or nonmalignant controls with high sensitivity and specificity, and high Receiver Operating Characteristics (DLBCL AUC = 0.96, MCL = 0.93, BL = 1.0). Longitudinal analysis showed that oncomiR levels reflect treatment efficacy and clinical outcomes, allowing their monitoring and prediction. In contrast to conventional methods, CSF oncomiRs enable detection of early and residual CNS involvement, as well as parenchymal involvement. These circulating oncomiRs increase 1-4 months before CNS relapse, allowing its early detection and improving the prediction of CNS relapse risk in DLBCL. Similar effects were detectable, to a lesser extent, in plasma.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22017204
003      
CZ-PrNML
005      
20220720100136.0
007      
ta
008      
220718s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers14092305 $2 doi
035    __
$a (PubMed)35565434
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Krsmanovic, Pavle $u Institute of Pathological Physiology, 1st Faculty of Medicine, Charles University, 128 53 Prague, Czech Republic $1 https://orcid.org/0000000311424282
245    10
$a Circulating microRNAs in Cerebrospinal Fluid and Plasma: Sensitive Tool for Detection of Secondary CNS Involvement, Monitoring of Therapy and Prediction of CNS Relapse in Aggressive B-NHL Lymphomas / $c P. Krsmanovic, H. Mocikova, K. Chramostova, M. Klanova, M. Trnkova, M. Pesta, P. Laslo, R. Pytlik, T. Stopka, M. Trneny, V. Pospisil
520    9_
$a Lymphoma with secondary central nervous system (CNS) involvement represents one of the most aggressive malignancies, with poor prognosis and high mortality. New diagnostic tools for its early detection, response evaluation, and CNS relapse prediction are needed. We analyzed circulating microRNAs in the cerebrospinal fluid (CSF) and plasma of 162 patients with aggressive B-cell non-Hodgkin's lymphomas (B-NHL) and compared their levels in CNS-involving lymphomas versus in systemic lymphomas, at diagnosis and during treatment and CNS relapse. We identified a set of five oncogenic microRNAs (miR-19a, miR-20a, miR-21, miR-92a, and miR-155) in CSF that detect, with high sensitivity, secondary CNS lymphoma involvement in aggressive B-NHL, including DLBCL, MCL, and Burkitt lymphoma. Their combination into an oncomiR index enables the separation of CNS lymphomas from systemic lymphomas or nonmalignant controls with high sensitivity and specificity, and high Receiver Operating Characteristics (DLBCL AUC = 0.96, MCL = 0.93, BL = 1.0). Longitudinal analysis showed that oncomiR levels reflect treatment efficacy and clinical outcomes, allowing their monitoring and prediction. In contrast to conventional methods, CSF oncomiRs enable detection of early and residual CNS involvement, as well as parenchymal involvement. These circulating oncomiRs increase 1-4 months before CNS relapse, allowing its early detection and improving the prediction of CNS relapse risk in DLBCL. Similar effects were detectable, to a lesser extent, in plasma.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Mocikova, Heidi $u Department of Haematology, University Hospital Kralovske Vinohrady and 3rd Faculty of Medicine, Charles University, 100 34 Prague, Czech Republic
700    1_
$a Chramostova, Kamila $u Institute of Pathological Physiology, 1st Faculty of Medicine, Charles University, 128 53 Prague, Czech Republic
700    1_
$a Klanova, Magdalena $u Institute of Pathological Physiology, 1st Faculty of Medicine, Charles University, 128 53 Prague, Czech Republic $u 1st Department of Medicine, Charles University General Hospital, 128 08 Prague, Czech Republic
700    1_
$a Trnkova, Marie $u 1st Department of Medicine, Charles University General Hospital, 128 08 Prague, Czech Republic
700    1_
$a Pesta, Michal $u Faculty of Mathematics and Physics, Charles University, 186 75 Prague, Czech Republic $1 https://orcid.org/0000000153110797 $7 xx0143725
700    1_
$a Laslo, Peter $u Section of Experimental Haematology, Leeds Institute of Cancer and Pathology, St James's University Hospital, University of Leeds, Leeds LS2 9JT, UK
700    1_
$a Pytlik, Robert $u Department of Cell Therapy, Institute of Haematology and Blood Transfusion, 128 20 Prague, Czech Republic
700    1_
$a Stopka, Tomas $u 1st Department of Medicine, Charles University General Hospital, 128 08 Prague, Czech Republic $u Biocev, 1st Faculty of Medicine, Charles University, 252 50 Vestec, Czech Republic
700    1_
$a Trneny, Marek $u 1st Department of Medicine, Charles University General Hospital, 128 08 Prague, Czech Republic
700    1_
$a Pospisil, Vit $u Institute of Pathological Physiology, 1st Faculty of Medicine, Charles University, 128 53 Prague, Czech Republic
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 14, č. 9 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35565434 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20220718 $b ABA008
991    __
$a 20220720100131 $b ABA008
999    __
$a ind $b bmc $g 1816484 $s 1168446
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 14 $c 9 $e 20220506 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
LZP    __
$a Pubmed-20220718

Find record

Citation metrics

Archiving options